Navigation Links
Former Stryker CEO Takes Reins at sBioMed
Date:11/1/2012

OREM, Utah, Nov. 1, 2012 /PRNewswire/ -- sBioMed, an emerging leader in infection control, announced today that Stephen P. MacMillan, former Chairman and CEO of Stryker, has joined the company as Chief Executive Officer and become an owner of the company.

sBioMed has developed breakthrough patented antimicrobial technologies, offering an unprecedented level of efficacy and safety. The company's flagship product STERIPLEX SD is the first and only Clostridium difficile sporicide and broad-spectrum, one-step disinfectant, which is also remarkably safe, completely non-fuming, non-corrosive, and contains no bleach.

The technology is similar to the company's anthrax remediation product, STERIPLEX Ultra, the only EPA-registered product available that kills anthrax spores.

Brian Larson, sBioMed's cofounder and chairman, said, "After a decade of research, over 500 studies and EPA-registration, we are excited to enter the full-scale commercialization process.  With Steve's leadership, we can help eliminate Healthcare-Associated Infections (HAIs) globally."

"It's rare to find a product with such revolutionary potential," MacMillan said. "STERIPLEX SD will save lives, improve healthcare delivery and protect caregivers, while reducing healthcare costs and preserving the environment.  I'm also excited about the chance to work with the sBioMed team to build a very special global company based in Utah."

With the growing incidence of C. diff and other superbugs, infections are now the fourth leading killer in the U.S., at a cost to the U.S. healthcare system of tens of billions of dollars annually.  Effective January 1, 2013, costs associated with HAIs will no longer be reimbursed, giving hospitals a strong incentive to eliminate HAIs. Hospitals currently employing STERIPLEX SD have charted a significant drop in HAIs.

STERIPLEX SD is EPA-registered for use on food contact surfaces (NSF D2) and can even be used on children's toys.  With the best MSDS health rating of "0," STERIPLEX SD provides broad-spectrum sporicidal disinfection for institutions that want to reduce HAIs, increase workplace safety, and eliminate their use of volatile organic compounds (VOCs).

Learn more about STERIPLEX on the company's website, www.steriplex.com.


'/>"/>
SOURCE sBioMed
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
2. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
3. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
4. PharmaVentures Helps Secure Investor for Former MSD Research Site
5. Dr. Michael Yaremchuk, Leading Performer of Custom-Designed Facial Implants, Pioneers Bespoke Plastic Surgery
6. Former FDA Inspectors Train Medical Device, Pharmaceutical Companies How to Prepare for FDA Inspections of Their Quality Systems
7. Ceres Expands Board of Directors with former BP Chief Scientist and Undersecretary of Energy Steven Koonin
8. New Kit Takes the Uncertainty Out of Lymphoma Diagnosis
9. Terminator-style info-vision takes step towards reality
10. Arteriocyte Takes the Lead in Promoting Building Future Pipeline of Women in STEM Career Fields
11. Quammen Health Care Consultants Takes Over Information Technology Reins at Faith Regional Health Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Research and Markets has announced the addition of ... and Companies" to their offering. ... The number of companies ... few years. More than 1,000 companies have been identified to ... are profiled in the report along with tabulation of 811 ...
(Date:1/17/2017)... ... 17, 2017 , ... One Million Solutions in Health announces, ... in investment towards 15+ TEC Validation Projects™. As a pre-competitive consortium, SafeTEC ... drug safety assessment, for the industry as a whole. , Through the SafeTEC ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... publication its decision on the appeal filed by India-based Dishman Pharmaceutical & Chemical ... contract against DPCL and one of its Dishman Group’s 100% wholly owned New ...
(Date:1/14/2017)... Jan. 13, 2017  The Alliance for Safe Biologic ... to FDA final guidance on biologic naming: ... leadership in emphasizing the importance of distinct naming for ... of the benefits biosimilars will bring to patients, including ... Yet the portion of the Guidance dealing with suffix ...
Breaking Biology Technology:
(Date:12/15/2016)... "Increase in mobile transactions is driving the ... market is expected to grow from USD 4.03 billion ... a CAGR of 29.3% between 2016 and 2022. The ... demand for smart devices, government initiatives, and increasing penetration ... is expected to grow at a high rate during ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market by ... Area, End User, And Region - Global Forecast to 2021", published by MarketsandMarkets, ... to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate (CAGR) ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... offering of €500.0 million principal amount of its 1.414% senior ... its 2.425% senior unsecured notes due 2026. ... December 13, 2016, subject to the satisfaction of customary closing conditions.  ... The Company intends to use the ...
Breaking Biology News(10 mins):